{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:04:41Z","timestamp":1782795881702,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study\u2019s purposes were to evaluate the impact of biological therapies on outcomes in patients with severe asthma (SA) and chronic rhinosinusitis (CRS) and to compare these effects among those with NP (CRSwNP) versus those without NP (CRSsNP) in the \u201creal-world\u201d setting in Saudi Arabian patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital\u2014Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), respectively. However, after 12 months of dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with CRS experienced significant improvements in clinical, FEV1, and laboratory outcomes after dupilumab therapy. However, these improvements were not maintained when comparing CRSwNP with CRSsNP. There were no significant differences between those with and without NP regarding ACT and OCs use or laboratory (eosinophilic count, serum IgE level) parameters. Further prospective multicenter studies are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-03139-x","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:02:25Z","timestamp":1720447345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of biological therapy in patients with severe asthma with chronic rhinosinusitis in Saudi Arabia: patients with nasal polyps versus those without nasal polyps"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-7062","authenticated-orcid":false,"given":"Usama E.","family":"Abuelhassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Elnamaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alfifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan K.","family":"Kadasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen A.","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salihah Y.","family":"Al-Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S.","family":"Kadasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Musleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawwaz A.","family":"Alshafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S. S.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmohsen Y.","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman I.","family":"Falqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader I.","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider M. O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasih U.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Amir","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R. I.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad M. A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"3139_CR1","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023. https:\/\/ginasthma.org\/2023-gina-main-report\/."},{"issue":"3","key":"3139_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213\u2013739. https:\/\/doi.org\/10.1002\/alr.22741.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"3139_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","volume":"46","author":"DE Shaw","year":"2015","unstructured":"Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308\u201321. https:\/\/doi.org\/10.1183\/13993003.00779-2015.","journal-title":"Eur Respir J"},{"issue":"10209","key":"3139_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: results from two multicentre, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"3","key":"3139_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Haan J, Lee SE, et al. The efficacy and safety of omalizumab in nasal polyps: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3139_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyposis and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133\u201341. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Supplement S29","key":"3139_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. A European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Supplement S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600.","journal-title":"Rhinology"},{"issue":"6","key":"3139_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/jpm12060976","volume":"12","author":"A Bakakos","year":"2022","unstructured":"Bakakos A, Schleich F, Bakakos P. Biological therapy of severe asthma and nasal polyps. J Pers Med. 2022;12(6):976. https:\/\/doi.org\/10.3390\/jpm12060976.","journal-title":"J Pers Med"},{"issue":"8","key":"3139_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/alr.22774","volume":"11","author":"S Bajpai","year":"2021","unstructured":"Bajpai S, Marino MJ, Rank MA, Donaldson AM, O\u2019Brien EK, Lal D. Benefits of biologic therapy for asthma on co-existent chronic rhinosinusitis: a real-world study. Int Forum Allergy Rhinol. 2021;11(8):1152\u201361. https:\/\/doi.org\/10.1002\/alr.22774.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"3139_CR10","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.waojou.2023.100746","volume":"16","author":"U F\u00f6rster-Ruhrmann","year":"2023","unstructured":"F\u00f6rster-Ruhrmann U, Stergioudi D, Szczepek AJ, Fluhr JW, Zuberbier T, Olze H, Bergmann KC. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyps treated with T2-biologics. World Allergy Organ J. 2023;16(2):100746. https:\/\/doi.org\/10.1016\/j.waojou.2023.100746.","journal-title":"World Allergy Organ J"},{"key":"3139_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/alr.21904","volume":"7","author":"R Divekar","year":"2017","unstructured":"Divekar R, Rank M, Squillace D, Kita H, Lal D. Unsupervised network mapping of commercially available immunoassay yields three distinct chronic rhinosinusitis endotypes. Int Forum Allergy Rhinol. 2017;7:373\u20139.","journal-title":"Int Forum Allergy Rhinol"},{"key":"3139_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alr.22101","volume":"8","author":"D Lal","year":"2018","unstructured":"Lal D, Hopkins C, Divekar RD. SNOT-22-based clusters in rhinosinusitis without nasal polyposis exhibit distinct endotypic and prognostic differences. Int Forum Allergy Rhinol. 2018;8:797\u2013805.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"3139_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, The American Thoracic Society \/ European Respiratory Society Task Force on Asthma Exacerbations, et al. An official American Thoracic Society\/European Respiratory Society statement: the asthma control and exacerbations: standardizing endpoints for clinical asthma trials & clinical practice. Am J Respir Crit Care Med. 2009;180(1):59\u201399. https:\/\/doi.org\/10.1164\/rccm.200801-060ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"3139_CR14","unstructured":"World Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"3139_CR15","doi-asserted-by":"publisher","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally significant difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124(4): 719\u2009\u2013\u200923.e1. https:\/\/doi.org\/10.1016\/j.jaci.2009.06.053.","DOI":"10.1016\/j.jaci.2009.06.053"},{"issue":"2","key":"3139_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4193\/Rhino15.072","volume":"54","author":"S Toma","year":"2016","unstructured":"Toma S, Hopkins C. Stratification of SNOT-22 scores into mild, moderate or severe and the relationship with other subjective instruments. Rhinology. 2016;54(2):129\u201333. https:\/\/doi.org\/10.4193\/Rhino15.072.","journal-title":"Rhinology"},{"issue":"2","key":"3139_CR17","doi-asserted-by":"publisher","first-page":"200058","DOI":"10.1183\/20734735.0058-2020","volume":"16","author":"S Khurana","year":"2020","unstructured":"Khurana S, Bush A, Holguin F. Management of severe asthma: summary of the European Respiratory Society\/American Thoracic Society task force report. Breathe (Sheff). 2020;16(2):200058. https:\/\/doi.org\/10.1183\/20734735.0058-2020.","journal-title":"Breathe (Sheff)"},{"key":"3139_CR18","doi-asserted-by":"publisher","first-page":"8102527","DOI":"10.1155\/2018\/8102527","volume":"2018","author":"S Mohamed Hussain","year":"2018","unstructured":"Mohamed Hussain S, Ayesha Farhana S, Mohammed Alnasser S. Time trends and Regional Variation in Prevalence of Asthma and Associated factors in Saudi Arabia: a systematic review and Meta-analysis. Biomed Res Int. 2018;2018:8102527. https:\/\/doi.org\/10.1155\/2018\/8102527. PMID: 29951546; PMCID: PMC5989288.","journal-title":"Biomed Res Int"},{"issue":"8","key":"3139_CR19","doi-asserted-by":"publisher","first-page":"e42818","DOI":"10.7759\/cureus.42818","volume":"15","author":"AR Khan","year":"2023","unstructured":"Khan AR, Waqar S, Rafiq Z, Bangash SA, Askar H, Khan MZ, Khan S. Retrospective analysis of Biologic Agent utilization in severe asthma: impact on Exacerbation Rates, forced Expiratory volume in the First Second (FEV1), Eosinophils, and IgE levels. Cureus. 2023;15(8):e42818. https:\/\/doi.org\/10.7759\/cureus.42818.","journal-title":"Cureus"},{"key":"3139_CR20","unstructured":"Prescribing information dupilumab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf."},{"key":"3139_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40733-020-00055-9","volume":"6","author":"E Kotisalmi","year":"2020","unstructured":"Kotisalmi E, Hakulinen A, M\u00e4kel\u00e4 M, Toppila-Salmi S, Kauppi P. A comparison of biologicals in treating adults with severe asthma: real-life experiences. Asthma Res Pract. 2020;6:2. https:\/\/doi.org\/10.1186\/s40733-020-00055-9.","journal-title":"Asthma Res Pract"},{"issue":"7","key":"3139_CR22","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","volume":"9","author":"J Bousquet","year":"2021","unstructured":"Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of Omalizumab in severe allergic asthma: a Meta-analysis of Observational studies. J Allergy Clin Immunol Pract. 2021;9(7):2702\u201314. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.011.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3139_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4168\/aair.2021.13.1.8","volume":"13","author":"BS Bochner","year":"2021","unstructured":"Bochner BS, Stevens WW. Biology and function of eosinophils in Chronic Rhinosinusitis with or without nasal polyps. Allergy Asthma Immunol Res. 2021;13(1):8\u201322. https:\/\/doi.org\/10.4168\/aair.2021.13.1.8.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"3139_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/alr.22234","volume":"9","author":"W Wang","year":"2019","unstructured":"Wang W, Gao Y, Zhu Z, Zha Y, Wang X, Qi F, et al. Changes in the clinical and histological characteristics of Chinese chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2019;9(2):149\u201357. https:\/\/doi.org\/10.1002\/alr.22234.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"3139_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaci.2005.02.029","volume":"115","author":"CA P\u00e9rez-Novo","year":"2005","unstructured":"P\u00e9rez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189\u201396. https:\/\/doi.org\/10.1016\/j.jaci.2005.02.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3139_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.alit.2019.11.002","volume":"69","author":"Y Yun","year":"2020","unstructured":"Yun Y, Kanda A, Kobayashi Y, Van Bui D, Suzuki K, Sawada S, et al. Increased CD69 expression on activated eosinophils in eosinophilic chronic rhinosinusitis correlates with clinical findings. Allergol Int. 2020;69(2):232\u20138.","journal-title":"Allergol Int"},{"issue":"5","key":"3139_CR27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (bevacizumab, dupilumab, mepolizumab, omalizumab, and reslizumab) for severe eosinophilic asthma. A systematic review for EAACI guidelines - recommendations on using biologicals in severe asthma. Allergy. 2020;75(5):1023\u201342. https:\/\/doi.org\/10.1111\/all.14221.","journal-title":"Allergy"},{"issue":"26","key":"3139_CR28","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"key":"3139_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","volume":"131","author":"CA Akdis","year":"2013","unstructured":"Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma&Immunology. JAllergy Clin Immunol. 2013;131:1479\u201390.","journal-title":"JAllergy Clin Immunol"},{"key":"3139_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2222.2008.03198.x","volume":"39","author":"X-H Zhang","year":"2009","unstructured":"Zhang X-H, Lu X, Long X-B, et al. Chronic rhinosinusitis with and without nasal polyps is associated with decreased expression of glucocorticoid-induced leucine zipper. Clin Exp Allergy. 2009;39:647\u201354.","journal-title":"Clin Exp Allergy"},{"key":"3139_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/lio2.303","volume":"4","author":"MJ Marino","year":"2019","unstructured":"Marino MJ, Garcia JO, Zarka M, Lal D. A structured histopathology-based analysis of surgical outcomes in chronic rhinosinusitis with and without nasal polyps. Laryngoscope Investig Otolaryngol. 2019;4:497\u2013503.","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"3139_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cea.12463","volume":"45","author":"RD Divekar","year":"2015","unstructured":"Divekar RD, Samant S, Rank MA, et al. Immunological profiling in chronic rhinosinusitis with nasal polyps reveals distinct VEGF and GM-CSF signatures during symptomatic exacerbations. Clin Exp Allergy. 2015;45:767\u201378.","journal-title":"Clin Exp Allergy"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03139-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:03:36Z","timestamp":1720447416000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03139-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3139"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03139-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Armed Forces Hospital Southern Region (AFHSR) Institutional Review Board (IRB) approved the study. The approval number is AFHSRMREC\/2022\/PULMONOLOGY-INTERNAL MEDICINE\/681. As the study is a retrospective analysis, the Armed Forces Hospital Southern Region (AFHSR) Institutional Review Board waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was not registered in any clinical trial registry and does not have a clinical trial number.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"328"}}